EP0215875A1 - Preparations pharmaceutiques immunomodulantes - Google Patents
Preparations pharmaceutiques immunomodulantesInfo
- Publication number
- EP0215875A1 EP0215875A1 EP19860901897 EP86901897A EP0215875A1 EP 0215875 A1 EP0215875 A1 EP 0215875A1 EP 19860901897 EP19860901897 EP 19860901897 EP 86901897 A EP86901897 A EP 86901897A EP 0215875 A1 EP0215875 A1 EP 0215875A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- sera
- group
- serums
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 3
- 230000002519 immonomodulatory effect Effects 0.000 title description 2
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 230000007170 pathology Effects 0.000 claims abstract description 5
- 239000000470 constituent Substances 0.000 claims abstract description 3
- 230000007123 defense Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 4
- 230000000781 anti-lymphocytic effect Effects 0.000 claims description 3
- 230000001079 digestive effect Effects 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 210000001539 phagocyte Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000003393 splenic effect Effects 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000003307 reticuloendothelial effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 abstract 1
- 210000003293 antilymphocyte serum Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000237 anti-lymphoid effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- TITLE Immunomodulating pharmaceutical preparations
- the present innovation makes it possible, by the same drug, to stimulate the general defenses of the organism on the one hand, and to improve the functioning of the affected tissue (s) in a privileged manner in the pathology specific to be treated on the other hand and this by the association of at least two constituents chosen from a different group from the following groups: the group of serums and / or the anti-lymphocyte and / or anti-lymphoid anti-tissue antibodies (ie GI the designation of this group) - the group of sera and (or) antibodies against phagocytic cells and (or) reticulohistiocytic antisystem (ie G2: the designation of this group - the group of sera and (or) target biologic anti-tissue antibodies specific pathology to be treated (ie G3: the designation of this group)
- serums and / or anti-mucous serums and / or anti-mucous, serous, muscular antibodies, osteoarticular, cardiovascular, pulmonary, hepatic, splenic, pancreatic, digestive, genital, urinary, glandular, nervous, connective tissue, etc.
- Example I (antilymphocyte serum)) antimacrophage serum)) nasopharyngosinus anti-mucosa serum)
- Example 2 anti-lymphocyte serum)) anti-macrophage serum)) anti-pulmonary tissue serum
- the presentations of these drugs can be solid or liquid in all possible pharmaceutical forms prepared according to methods known to those skilled in the art.
- the active ingredients can be incorporated into all possible vehicles and excipients used in pharmaceutical compositions.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8503964A FR2587217B1 (fr) | 1985-03-18 | 1985-03-18 | Preparations pharmaceutiques immunomodulantes |
FR8503964 | 1985-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0215875A1 true EP0215875A1 (fr) | 1987-04-01 |
Family
ID=9317295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19860901897 Withdrawn EP0215875A1 (fr) | 1985-03-18 | 1986-03-17 | Preparations pharmaceutiques immunomodulantes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0215875A1 (fr) |
AU (1) | AU5627586A (fr) |
FR (1) | FR2587217B1 (fr) |
WO (1) | WO1986005398A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2620335A1 (fr) * | 1987-09-15 | 1989-03-17 | Berdal Pascal | Presentation pharmaceutique potentialisant l'effet cytotrophique des serums et/ou des anticorps antitissus animaux et/ou humains |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR6259M (fr) * | 1967-02-06 | 1968-08-19 | ||
FR2216998B1 (fr) * | 1973-02-08 | 1976-05-14 | Choay Sa | |
FR2487201B2 (fr) * | 1980-03-24 | 1985-07-05 | Pasteur Institut | Preparation lymphocytaires applicables en therapeutique humaine, procede d'obtention et applications |
FR2478470A1 (fr) * | 1980-03-24 | 1981-09-25 | Pasteur Institut | Preparations cellulaires applicables en therapeutique humaine, procede d'obtention et applications |
-
1985
- 1985-03-18 FR FR8503964A patent/FR2587217B1/fr not_active Expired - Lifetime
-
1986
- 1986-03-17 WO PCT/FR1986/000088 patent/WO1986005398A1/fr not_active Application Discontinuation
- 1986-03-17 AU AU56275/86A patent/AU5627586A/en not_active Abandoned
- 1986-03-17 EP EP19860901897 patent/EP0215875A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO8605398A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU5627586A (en) | 1986-10-13 |
FR2587217A1 (fr) | 1987-03-20 |
FR2587217B1 (fr) | 1991-10-18 |
WO1986005398A1 (fr) | 1986-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100446170B1 (ko) | 사이클로스포린을함유하는약학조성물 | |
JP3644543B2 (ja) | シクロスポリンA及びα−トコフェロールを含有する医薬組成物 | |
DeBold et al. | Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. | |
JPH07508724A (ja) | Nsaidおよび胆汁酸を含む薬剤組成物 | |
CA2181422A1 (fr) | Formulations galeniques du fenofibrate et leurs applications | |
CA2077647A1 (fr) | Formulation topique de cyclosporine | |
JPH11505257A (ja) | 親油性薬物の自己乳化性製剤 | |
CN1152876A (zh) | 供局部施用于眼组织的泪腺特异性乳状液 | |
EP0696920A1 (fr) | Compositions ameliorees, pharmaceutiquement acceptables, contenant un alcool et un medicament hydrophobe | |
CA2395121C (fr) | Composition, notamment cosmetique ou dermatologique, contenant des oligosaccharides, son procede de preparation et un procede de traitement cosmetique | |
Rajasree et al. | Biochemical effects of garlic protein on lipid metabolism in alcohol fed rats | |
EP0215875A1 (fr) | Preparations pharmaceutiques immunomodulantes | |
US4254103A (en) | Hepatoprotector Factor (HF) and method of treatment | |
CA2025018A1 (fr) | Composes contenant de la thymopentine pour le traitement topique des affections cutanees | |
CA2677404C (fr) | Utilisation d'argiles pour le traitement de la maladie coeliaque | |
MIYASAKA | Steroid-resistant Weber-Christian disease | |
CA2224792C (fr) | Preparation pharmaceutique contenant de la cyclosporine a | |
Dange et al. | Effect of ‘Arogyavardhini’against carbon tetrachloride induced hepatic damage in albino rats | |
RU2810897C2 (ru) | Фармацевтические составы аналогов циклоспорина | |
US7078437B2 (en) | Apolipoprotein D degradation inhibitor | |
WO2022135462A1 (fr) | Utilisation médicale d'inhibiteur de magl | |
Jain et al. | Effect of T‐tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil | |
Fujimura et al. | Chronopharmacology of probucol in mice | |
FR2569563A1 (fr) | Formulation a base de benzoylecgonine ou de benzoylnorecgonine pour le traitement du rhumatisme articulaire | |
Miller et al. | Small vessel vasculitis presenting as neurological disorder. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BERDAL, PASCAL |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE FR GB IT NL SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE FR GB IT |
|
17P | Request for examination filed |
Effective date: 19870525 |
|
17Q | First examination report despatched |
Effective date: 19900622 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19910521 |
|
R18W | Application withdrawn (corrected) |
Effective date: 19910521 |